Solid Biosciences Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Solid Biosciences Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $8.09M | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $13.62M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 14, 2022 |
| FY2019 | Dec 31, 2019 | $0 | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | $0 | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | $0 | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 12, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Mar 12, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Mar 12, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | ($117.22M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2018 | ($21.92M) | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | ($19.02M) | Mar 13, 2019 |
| FY2018 | Jun 30, 2018 | ($17.98M) | Mar 13, 2019 |
| FY2018 | Mar 31, 2018 | ($15.88M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2017 | ($14.49M) | Mar 13, 2019 |
| FY2018 | Sep 30, 2017 | ($13.51M) | Mar 13, 2019 |
| FY2018 | Jun 30, 2017 | ($11.31M) | Mar 13, 2019 |
| FY2018 | Mar 31, 2017 | ($12.82M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | ($21.54M) | Mar 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($179.21M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($129.73M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($104.25M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($106.45M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | ($72.25M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($88.41M) | Mar 23, 2023 |
| FY2019 | Dec 31, 2019 | ($32.33M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($29.72M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($26.97M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($30.30M) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.33M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $96.43M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $76.56M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $78.42M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $58.74M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $64.88M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $94.74M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $57.97M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $39.91M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $20.12M | Mar 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($156.29M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($100.01M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($94.18M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($97.98M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | ($77.76M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($56.60M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($92.71M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | ($70.20M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($43.22M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($20.12M) | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $654.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.52M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $3.02M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $1.28M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $899.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.39M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $7.78M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $2.28M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $392.0K | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.54M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $188.66M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $164.94M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $260.25M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $232.38M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $171.17M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $103.47M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $139.60M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $76.19M | Mar 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.53M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $51.42M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $38.46M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $48.59M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $24.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $39.08M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $23.42M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $14.41M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $11.27M | Mar 13, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.01M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $137.25M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $126.48M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $211.67M | Mar 6, 2025 |
| FY2022 | Dec 31, 2021 | $208.21M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $132.09M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $80.05M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $125.18M | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($957.78M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($783.45M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($658.75M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($562.74M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($476.76M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($404.57M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($316.28M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($199.06M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($124.26M) | Mar 13, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.90M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $80.24M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $74.02M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $155.38M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $119.14M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $154.74M | Mar 23, 2023 |
| FY2022 | Dec 31, 2019 | $76.04M | Mar 23, 2023 |
| FY2021 | Dec 31, 2018 | $86.37M | Mar 14, 2022 |
| FY2019 | Dec 31, 2017 | $52.08M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $7.68M | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | (10) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | (25) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | (10) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | (25) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.97M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 40.47M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 20.39M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 19.56M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 7.36M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 84.89M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 45.99M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 35.43M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 13, 2019 |